Adcendo Extends Series A Financing to €98M
Adcendo ApS, a biotech company specializing in revolutionary antibody-drug conjugates (ADCs) for treating cancers with significant medical needs, has announced the successful completion of a second round of Series A extension financing. This funding has raised a total of 98M EUR, with an additional 16M EUR led by Dawn Biopharma, a platform controlled by KKR. Existing investors such as Novo Holdings, Ysios Capital, RA Capital Management, HealthCap, Gilde Healthcare, and Pontifax Venture Capital also participated in this financing. As part of the investment, Iyona Rajkomar, Managing Partner at Dawn Biopharma, will join the Adcendo Board of Directors.
With this funding, Adcendo aims to strengthen the development of its groundbreaking ADC pipeline assets and expand the development strategy for its leading uPARAP program, targeting soft tissue sarcoma and other mesenchymal cancers. Moreover, the funds will be utilized to advance the discovery-stage of additional first-in-class ADC pipeline assets towards Development Candidate Nomination and beyond.
More Information : https://www.techdogs.com/tech-news/pr-newswire/adcendo-aps-announces-extension-of-series-a-financing-to-eur-98m-to-further-bolster-its-first-in-class-adc-pipeline
Comments
Post a Comment